Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients.
Thill
Marc
M
Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. marc.thill@uk-sh.de
Fischer
Dorothea
D
Kelling
Katharina
K
Hoellen
Friederike
F
Dittmer
Christine
C
Hornemann
Amadeus
A
Salehin
Darius
D
Diedrich
Klaus
K
Friedrich
Michael
M
Becker
Steffi
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002112:Calcifediol / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D015232:Dinoprostone / Q000378:metabolism*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000096:biosynthesis*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000378:metabolism*; D010053:Ovary / Q000201:enzymology* / Q000378:metabolism*; D018167:Receptors, Calcitriol / Q000096:biosynthesis*
D018167:Receptors, Calcitriol; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; D051546:Cyclooxygenase 2; D015232:Dinoprostone; D002112:Calcifediol